ArticleCureus2025
A Case of Primary Malignant Melanoma of the Nasolacrimal Duct.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Primary Malignant Melanoma of the Nasolacrimal Duct Presenting Without Hemolacria: A Case Report and Literature Review.Current oncology (Toronto, Ont.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant melanoma of the nasal cavity and paranasal sinuses is an extremely rare disease, with only a few reported cases originating from or extending into the nasolacrimal duct. Multimodal treatments, including surgery, radiotherapy, chemotherapy, immunotherapy, and immune checkpoint inhibitors, have been attempted; however, the treatment outcomes remain unsatisfactory. We herein report a case of primary malignant melanoma of the nasolacrimal duct, which was successfully managed through complete en bloc resection of the nasolacrimal duct along with the surrounding bony structures, lacrimal sac, and puncta, followed by adjuvant radiotherapy and administration of immune checkpoint inhibitors. This multidisciplinary approach resulted in a favorable clinical course. Due to the rarity of mucosal malignant melanoma, many aspects of the disease remain unclear, and further evidence is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.